Ranbaxy Launches Patient Education Resources for Acne Patients Featuring Athlete Kelly Clark
Ranbaxy Laboratories Inc, a SUN PHARMA company, has launched of a variety of patient education resources featuring gold medal-winning snowboarder and 2015 ESPY Best Female Action Sports Athlete Kelly Clark. The tools are housed on ABSORICA.COM.
Absorica® (isotretinoin) capsules are indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Kelly has struggled with the condition since her early teens, but recently was successfully treated with Absorica, not only clearing her skin, but also changing her outlook on life. In an effort to provide physicians, patients (and their parents) with educational materials about the use of isotretinoin treatment, Kelly shares her experience living with the condition, her recent treatment with Absorica and her participation in the iPledge program during her regimen.
As a professional athlete living a public life, Kelly shares that severe acne was a constant challenge that took its toll on her confidence socially and when interviewed on-camera. After trying many different methods to treat the condition, she was diagnosed with severe recalcitrant nodular acne and underwent a 5-month treatment regimen on Absorica. She chronicled her treatment journey, taping bi-weekly video logs in which she shared her progress, challenges, and observations about her skin.
The following patient-education resources can be found on ABSORICA.COM:
- Bi-weekly Vlogs: Kelly recorded herself, naturally and candidly sharing updates and observations as her treatment progressed.
- Patient Information Video: Kelly and her treating dermatologist, Ingird Trenkle, MD, are featured in an engaging and highly informative short video that addresses some of the common side-effects and concerns surrounding isotretinoin therapy, as well as the requirements of iPledge participation .
- An all-new patient brochure featuring testimonials from real-life patients, including Kelly, who found success with Absorica.